NASDAQ:ATOS Atossa Genetics Q2 2025 Earnings Results & Report $2.14 +0.01 (+0.47%) Closing price 04:00 PM EasternExtended Trading$2.12 -0.02 (-1.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Atossa Genetics missed analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$1.05 versus the -$0.90 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call8:30 AM ET Atossa Genetics EPS ResultsActual EPS-$1.05Consensus EPS -$0.90Beat/MissMissed by -$0.15One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAtossa Genetics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAtossa Genetics' next earnings date is estimated for Tuesday, November 10, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atossa Genetics Q2 2025 Earnings FAQ Did Atossa Genetics beat earnings estimates for Q2 2025? Atossa Genetics (NASDAQ:ATOS) reported earnings of -$1.05 per share for Q2 2025, missing the consensus estimate of -$0.90. The report was announced on Tuesday, August 12, 2025. When is Atossa Genetics' next earnings date? Atossa Genetics' next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Atossa Genetics on the company's earnings history page. Atossa Genetics Earnings HeadlinesAtossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateNovember 10 at 8:15 AM | prnewswire.comAtossa Genetics (ATOS) Expected to Announce Earnings on WednesdayNovember 10 at 1:57 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business TodayOctober 19, 2026 | prnewswire.comAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueOctober 9, 2026 | prnewswire.comAtossa plans shareholder stake in potential PRV proceedsSeptember 30, 2026 | msn.comSee More Atossa Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atossa Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atossa Genetics and other key companies, straight to your email. Email Address About Atossa GeneticsAtossa Genetics (NASDAQ:ATOS), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer. Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company has evaluated the therapy in clinical studies involving patients with breast cancer and continues to advance its development through additional research and clinical testing. Headquartered in Seattle, Washington, Atossa conducts its development activities through clinical research and collaborations with medical institutions and investigators. The company was founded in 2009 and initially pursued products and technologies related to breast health and cancer diagnostics before focusing more heavily on therapeutic development.View Atossa Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
